Key Highlights

  • Indaptus Therapeutics shares closed up 23% at $2.56.
  • The rise followed the company's second-quarter 2026 update.
  • The update emphasized enhanced Capital reserves via a $12.0 million private placement.
  • The company is actively evaluating strategic Options for Decoy20 and core operations, including partnerships, Equity investments, asset purchases, or mergers.

Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares closed up 23% at $2.56 following its second-quarter 2026 update, which emphasized enhanced capital reserves via a $12.0 million private placement.

What Happened

The company is actively evaluating strategic options for Decoy20 and its core operations, encompassing potential partnerships, equity investments, asset purchases, or corporate mergers, coupled with an initial research venture spanning neurological conditions and sleep medicine.

Market Reaction

Shares rose as investors responded to the strengthened capital position and the range of strategic alternatives under evaluation for the company's Decoy20 program and broader operations.

Outlook

The outcome of Indaptus Therapeutics' strategic options review for Decoy20 and its core operations, along with progress on its new neurological and sleep medicine research venture, represent the next relevant developments for the company.